In vivo response to chemotherapy, distribution of types of event and of survival status of children with T-ALL according to genetic subgroups
. | Total population studied, n . | Subgroup . | . | . | . | All HOX11L2-negative, n† . | |||
|---|---|---|---|---|---|---|---|---|---|
. | . | HOX11L2-positive, n . | HOX11-high, n . | SIL-TAL, n . | Other, n* . | . | |||
| Total, N (%) | 127 (100) | 34 (100) | 9 (100) | 15 (100) | 69 (100) | 117 (100) | |||
| Response to prephase | |||||||||
| Died before evaluation | 1 (0.8) | 0 (0) | 0 (0) | 1 (6.7) | 0 (0) | 1 (0.9) | |||
| Less than 1000 blasts/μL | 79 (62.2) | 24 (70.6) | 9 (100) | 7 (46.7) | 39 (56.5) | 67 (62.6) | |||
| At least 1000 blasts/μL | 47 (37.0) | 10 (29.4) | 0 (0) | 7 (46.7) | 30 (43.5) | 39 (36.4) | |||
| MRD‡ | |||||||||
| ND | 59 (46.5) | 15 (44.1) | 4 (44.4) | 8 (53.3) | 32 (46.4) | 55 (51.4) | |||
| Absence of marker | 12 (9.4) | 1 (2.9) | 1 (11.1) | 0 (0.0) | 10 (14.5) | 11 (10.3) | |||
| Less than 10-2 | 46 [82.1] | 13 [72.2] | 4 [100] | 7 [100] | 22 [81.5] | 35 [85.4] | |||
| At least 10-2 | 10 [17.9] | 5 [27.8] | 0 [0] | 0 [0] | 5 [18.5] | 6 [14.6] | |||
| Type of event | |||||||||
| No event (ie, in CCR) | 94 (74.0) | 25 (73.5) | 8 (88.9) | 12 (80.0) | 49 (71.0) | 25 (73.5) | |||
| No CR | 4 (3.1) | 0 (0) | 0 (0) | 1 (6.7) | 3 (4.3) | 5 (4.7) | |||
| BM only | 12 (9.4) | 4 (11.8) | 0 (0) | 2 (13.3) | 6 (8.7) | 8 (7.5) | |||
| CNS only | 3 (2.4) | 0 (0) | 0 (0) | 0 (0) | 3 (4.3) | 7 (6.5) | |||
| Other isolated relapse | 1 (0.8) | 0 (0) | 0 (0) | 0 (0) | 1 (1.4) | 1 (0.9) | |||
| Combined | 9 (7.1) | 4 (11.8) | 1 (11.1) | 0 (0) | 4 (5.8) | 5 (4.7) | |||
| Death in CR | 4 (3.1) | 1 (2.9) | 0 (0) | 0 (0) | 3 (4.3) | 3 (2.8) | |||
| Survival status | |||||||||
| Alive | 99 (78.0) | 27 (79.4) | 9 (100) | 14 (93.3) | 49 (71.0) | 82 (76.6) | |||
| Dead | 28 (22.0) | 7 (20.6) | 0 (0) | 1 (6.7) | 20 (29.0) | 25 (23.4) | |||
. | Total population studied, n . | Subgroup . | . | . | . | All HOX11L2-negative, n† . | |||
|---|---|---|---|---|---|---|---|---|---|
. | . | HOX11L2-positive, n . | HOX11-high, n . | SIL-TAL, n . | Other, n* . | . | |||
| Total, N (%) | 127 (100) | 34 (100) | 9 (100) | 15 (100) | 69 (100) | 117 (100) | |||
| Response to prephase | |||||||||
| Died before evaluation | 1 (0.8) | 0 (0) | 0 (0) | 1 (6.7) | 0 (0) | 1 (0.9) | |||
| Less than 1000 blasts/μL | 79 (62.2) | 24 (70.6) | 9 (100) | 7 (46.7) | 39 (56.5) | 67 (62.6) | |||
| At least 1000 blasts/μL | 47 (37.0) | 10 (29.4) | 0 (0) | 7 (46.7) | 30 (43.5) | 39 (36.4) | |||
| MRD‡ | |||||||||
| ND | 59 (46.5) | 15 (44.1) | 4 (44.4) | 8 (53.3) | 32 (46.4) | 55 (51.4) | |||
| Absence of marker | 12 (9.4) | 1 (2.9) | 1 (11.1) | 0 (0.0) | 10 (14.5) | 11 (10.3) | |||
| Less than 10-2 | 46 [82.1] | 13 [72.2] | 4 [100] | 7 [100] | 22 [81.5] | 35 [85.4] | |||
| At least 10-2 | 10 [17.9] | 5 [27.8] | 0 [0] | 0 [0] | 5 [18.5] | 6 [14.6] | |||
| Type of event | |||||||||
| No event (ie, in CCR) | 94 (74.0) | 25 (73.5) | 8 (88.9) | 12 (80.0) | 49 (71.0) | 25 (73.5) | |||
| No CR | 4 (3.1) | 0 (0) | 0 (0) | 1 (6.7) | 3 (4.3) | 5 (4.7) | |||
| BM only | 12 (9.4) | 4 (11.8) | 0 (0) | 2 (13.3) | 6 (8.7) | 8 (7.5) | |||
| CNS only | 3 (2.4) | 0 (0) | 0 (0) | 0 (0) | 3 (4.3) | 7 (6.5) | |||
| Other isolated relapse | 1 (0.8) | 0 (0) | 0 (0) | 0 (0) | 1 (1.4) | 1 (0.9) | |||
| Combined | 9 (7.1) | 4 (11.8) | 1 (11.1) | 0 (0) | 4 (5.8) | 5 (4.7) | |||
| Death in CR | 4 (3.1) | 1 (2.9) | 0 (0) | 0 (0) | 3 (4.3) | 3 (2.8) | |||
| Survival status | |||||||||
| Alive | 99 (78.0) | 27 (79.4) | 9 (100) | 14 (93.3) | 49 (71.0) | 82 (76.6) | |||
| Dead | 28 (22.0) | 7 (20.6) | 0 (0) | 1 (6.7) | 20 (29.0) | 25 (23.4) | |||
Numbers in parentheses and brackets are percentages. CCR indicates continuous complete remission; BM, bone marrow relapse; CNS, central nervous system relapse.
Negative for 3 genetic markers.
This group included 107 patients: 9 patients with HOX11-high, 15 patients positive for SIL-TAL, 69 patients with other, and 14 additional patients who tested negative for HOX11L2 and not tested for HOX11 and SIL-TAL status.
Percentages between [] were calculated taking into account only documented cases.